Amplia Therapeutics (ASX:ATX) completes design for Phase 2 trial in first-line pancreatic cancer patients
Amplia Therapeutics (ATX) completes the design for a Phase 2 clinical trial…
Amplia Therapeutics Limited (ATX:ASX)
21.0¢
0.005 (2.44%)
MCAP $25.58M
Last trade
13.00pm 17/09/2021
20mins delayed
Latest Announcements
15/09/2021 Price SensitivePSATXAmplia Therapeutics Limited
15/09/2021ATXAmplia Therapeutics Limited
154
MCap
06/09/2021ATXAmplia Therapeutics Limited
27/08/2021ATXAmplia Therapeutics Limited
2,179
MCap
27/08/2021 Price SensitivePSATXAmplia Therapeutics Limited
20/08/2021ATXAmplia Therapeutics Limited
171
MCap
28/07/2021 Price SensitivePSATXAmplia Therapeutics Limited
26/07/2021ATXAmplia Therapeutics Limited
253
MCap
Company Overview
Amplia Therapeutics Limited is an Australia-based clinical-stage drug development company. The Company’s pipeline is developing two orally available small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its initial clinical development pipeline consists of AMP945 and AMP886 (FLT3/VEGFR3). The Company’s cancer program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its Fibrosis Program is the formation of excessive fibrous connective tissues that can result from chronic inflammation, chronic injury or disease. Its FAK inhibitors have been shown to block fibrosis in established animal models of both lung fibrosis and liver fibrosis (NASH).
